source
- Vertex Q1 revenue slightly below forecasts as key drug sales miss estimates, but Alyftrek revenue surgesVertex Pharmaceuticals reported first‑quarter revenue of about $3 billion, falling just short of Wall Street expectations. The modest miss left the stock largely unchanged on the day of the release…
- Viridian's elegrobart shows strong results in chronic thyroid eye disease trial, challenging Amgen's TepezzaViridian Therapeutics announced that its injectable drug elegrobart met its primary goals in a late-stage study of patients with chronic thyroid eye disease. The trial reported response rates of 50…